Specific inhibitors of HIF-2α have recently been approved for the treatment of ccRCC in VHL disease patients and have shown encouraging results in clinical trials for metastatic sporadic ccRCC. Here, EPAS1 is linked to nonpapillary renal cell carcinoma.